The impact of biosimilars in 2018: ‘Treating a third more people, at half the cost’
2018 saw an increase in the number of biosimilar approvals, and the expiry of patents on major products that allowed the entry of biosimilars across Europe.
2018 saw an increase in the number of biosimilar approvals, and the expiry of patents on major products that allowed the entry of biosimilars across Europe.
Eli Lilly will acquire Loxo for $8bn to gain access to treatments that target cancers dependent on single gene abnormalities.